Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
bispecific antibodies
Biotech
FDA blocks approval of Regeneron's blood cancer drug
Regeneron may have gotten ahead of itself with the early filing of bispecific antibody odronextamab to regulators.
James Waldron
Mar 25, 2024 9:25pm
Hansoh signs $690M ADC pact with fellow Chinese biotech Biotheus
Mar 15, 2024 8:35am
Pfizer cuts 3 assets as R&D spend drops 24% in Q4
Jan 30, 2024 11:37am
ASH: Regeneron’s near-approval bispecific shines again
Dec 11, 2023 5:25am
Regeneron's 'best-in-class' myeloma drug spurs 100% side effects
Dec 7, 2023 7:00am
Merus shares dip as lung cancer data reveal 3 patient deaths
Dec 4, 2023 1:04pm